Abstract

DEVELOPMENT OF VERAPAMIL AND TRANDOLAPRIL BILAYER TABLET AND INVITRO EVALUATION

Abdul Mannan and *Syeda Ayesha Farheen

ABSTRACT

Hypertension is a pressing global health issue, contributing to an increase in cardiovascular risk, as well as being the most common condition. The primary goal of reducing BP is to decrease the long-term risks of cardiovascular morbidity and mortality. Drug Combination with two or more agents is the most effective method for achieving strict blood pressure goals. High performance liquid chromatography is performed using column C18. The different mobile phases are used in different ratios and different peaks are obtained. The method was developed and validated using symmetrical C18 column (4.6 x 150mm, 3.5consisted of potassium dihyrogen ortho phosphate buffer (pH2.2): acetonitrile [35:65 v/v] at a flow rate of 0.6ml /min and UV detection wavelength was at 230 nm. The retention time for verapamil hydrochloride was 2.5min and trandolapril was at 3.8min. The linearity range of verapamil hydrochloride and trandolapril were in the range of 10μg/ml to 65μg/ml and 2μg/ml to15μg/ml respectively. The method was validated as per the ICH guidelines and successfully applied to the marketed product. The method was found to be simple, rapid, precise and accurate.

Keywords: Verapamil hydrochloride, Trandolapril, HPLC method development and Validation.